Gate Bioscience Secures $60M in Series A Funding to Pioneer Molecular Gate Medicines for Disease Elimination

Gate Bioscience is excited to announce a remarkable funding milestone, having raised $60,000,000 in its latest round of investment. This infusion of capital marks a significant leap forward for the pioneering preclinical biotechnology company, which is at the forefront of developing a transformative class of therapeutics known as Molecular Gates. These innovative small molecule drugs are uniquely designed to selectively eliminate harmful extracellular proteins directly at their source—inside the cell. By targeting over 1,000 disease-driving extracellular proteins among the more than 4,000 naturally produced by the human body, Gate Bioscience is poised to address a broad range of conditions caused by proteins that act improperly, misfold, or are produced out-of-sync with the body’s needs. The Molecular Gates platform introduces a disruptive therapeutic mechanism, wherein every extracellular protein must transit through a single secretory channel. By binding to this channel selectively, Molecular Gates effectively set up a “gate” that prevents the exit of specific proteins responsible for disease. With no alternative pathway, these proteins are retained and subsequently degraded within the cell, potentially halting the progression of debilitating diseases. The newly raised funds will be strategically deployed to accelerate preclinical research and development, streamline regulatory processes, and expand partnerships that are critical to advancing Molecular Gate medicines from concept to clinical reality. Backed by leading investors including Versant Ventures, a16z Bio + Health, ARCH Venture Partners, and GV, Gate Bioscience is committed to transforming patient care by eliminating deadly proteins at their source. To learn more about this groundbreaking approach and upcoming milestones, visit www.gatebio.com.